|Home | About | Journals | Submit | Contact Us | Français|
Since 1992, research teams from Indiana University and the University of Ibadan have been collecting and comparing data from two diverse, elderly populations to identify risk factors for dementia and Alzheimer’s disease. Apolipoprotein E (APOE) was genotyped in 2,245 Nigerian samples. Of these, 830 had a diagnosis: 459 were normal, and 140 had dementia including 123 diagnosed with Alzheimer’s disease. In contrast with other populations, the APOE ε4 allele was not significantly associated with Alzheimer’s disease or dementia. This lack of association in the Yoruba might reflect genetic variation, environmental factors, as well as genetic/environmental interactions.
Alzheimer’s disease (AD) is the most common form of dementia, accounting for a major part of public health spending in many developed societies1 and becoming an economic burden in developing countries. 2 A meta-analysis including data from several ethnic groups showed that the ε4 allele of apolipoprotein E gene (APOE) constitutes a major susceptibility factor for the development of AD.3 However, this relation appears less consistent among African American4,5 and Hispanic4 populations.
We have previously published our prevalence findings on the relation between APOE and the risk for AD in the Indianapolis-Ibadan Dementia Study, a longitudinal, cross-cultural study of AD in African Americans in Indianapolis and the Yoruba in Ibadan, Nigeria. 6,7 Among African Americans, a significant association between ε4 and AD was observed, with the association being dose dependent.6 In the Yoruba, neither one nor two ε4 alleles were associated with an increased risk for AD. However, only 12 Yoruba subjects had AD among the 56 samples that were genotyped.7
Since this report was published, we have APOE genotypes on 2,245 Ibadan subjects and clinical assessments on 830, including 123 with AD. Our results are presented here.
Data are derived from a population-based study on the prevalence and incidence of AD and dementia in Yoruba 65 years or older (n = 4,425). The original cohort of 2,212 was enriched by an additional prevalence wave in 2001. A detailed description of the study methodology has been published previously.8 Institutional review boards at both the University of Ibadan and Indiana University have approved the study protocol. Only individuals who provided signed informed consent were studied. Data were collected from a baseline wave conducted in 1992 and 1993 and follow-up evaluations conducted 2, 5, and 8 years after baseline. At each wave, a two-phase design was used. In the first phase, subjects were interviewed in their homes using the Community Screening Instrument for Dementia.9 Based on the screening performance, selected participants received a full diagnostic workup in the second phase.
At each follow-up wave, study participants were divided into three performance groups: good, intermediate, and poor. Group division was based on the subjects’ current screening scores. In addition, change scores from previous waves were calculated. Subjects were also categorized into poor, intermediate, and good change groups. Cutoff points on change scores were derived so that approximately 5% of subjects with the worst change scores (most declines) were in the poor change group and approximately 8% of subjects with the next worst change scores were in the intermediate change group. The cross-sectional and longitudinal groupings were combined into one in which subjects were categorized by the worst of the two. All subjects falling into the poor performance group were chosen for clinical assessment to ensure that participants with the greatest probability of having dementia would be diagnosed. Participants were randomly sampled from the intermediate performance group until 50% had clinical assessments and from the good performance group (weighted for 75% of age 75 years and older) until 5% had clinical assessments.
Clinical evaluations consisted of an informant interview, neuropsychological testing, and examination by a physician. Diagnoses of normal, cognitive impairment, or dementia were made by consensus of study physicians and neuropsychologists from both sites. For a diagnosis of dementia, both International Classification of Diseases, 10th Revision (ICD-10)10 and Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R)11 criteria had to be met. The National Institute for Neurological and Communicative Diseases and Stroke-Alzheimer Disease and Related Disorders Association criteria were used for diagnosis of probable and possible AD.12
Only subjects who had an APOE genotype and a clinical evaluation were included in this study. The demented or AD group consists of subjects who were diagnosed with dementia or AD at any time throughout the course of the study. Of the remaining subjects evaluated clinically, subjects were classified according to the diagnosis of their most recent clinical assessment. Those who were diagnosed as normal at their most recent clinical assessment were considered normal. Subjects whose most recent diagnosis was cognitive impairment were excluded from this analysis. Demographic characteristics and APOE allele frequencies were compared with t tests for continuous variables and χ2 tests for categorical variables. Logistic regression models adjusting for age at diagnosis, gender, and formal education (any vs none) were used to calculate the odds ratios and 95% confidence intervals for AD and dementia for various APOE genotypes, using the ε3/ε3 genotype as the reference group. p values less than 0.05 were considered statistically significant.
A total of 2,245 DNA samples were genotyped for APOE. Of these samples, 830 participants had a clinical diagnosis. No significant differences were seen in the frequency of the APOE genotypes between the clinically evaluated subjects and those without a clinical evaluation (p = 0.3898). However, the subjects with a clinical diagnosis are significantly older (73.9 ± 8.0 vs 73.0 ± 5.7; p = 0.0054), more likely to be female (71.8% vs 62.9%; p < 0.0001), and had no formal education (87.4% vs 84.2%; p = 0.0391). These differences were expected because there is oversampling of the poor performance group.
Of the 830 clinically evaluated subjects, 459 were normal and 140 were diagnosed with dementia (38 subjects at prevalence and 102 at incidence), of which 123 were diagnosed with AD (30 subjects at prevalence and 93 at incidence). The remaining 231 subjects were diagnosed with cognitive impairment and left out of the analyses. Table 1 shows the baseline characteristics and APOE genotype and allele frequencies for subjects with each diagnosis. There was a significant difference in gender between both the demented and AD groups and normal subjects (demented vs normal: p = 0.0017; AD vs normal: p < 0.0001). Subjects with dementia and AD were significantly older than normal subjects (p < 0.0001 for both comparisons). In addition, the demented and AD groups contained less subjects who attended school (p = 0.0295 and 0.0075, respectively). All subjects were followed for similar amounts of time (demented vs normal: p = 0.1025; AD vs normal: p = 0.0637). Follow-up times for those with and without ε4 were similar (5.4 vs 5.2 years, respectively).
None of the APOE alleles were significantly increased in the AD (ε2: p = 0.6717; ε3: p = 0.3171; ε4: p = 0.1484) or dementia (ε2: p = 0.4878; ε3: p = 0.7226; ε4: p = 0.3586) groups compared with normal subjects. There were no significant differences in the distributions of the number of ε4 alleles between the AD (p = 0.3570) or demented (p = 0.6578) subjects and normal subjects.
Logistic regression results of the association of APOE with AD or dementia, after adjusting for gender, age at diagnosis, and education, are shown in Table 2. Again, there were no significant differences in the number of subjects with one or two copies of ε4 among the groups. In addition, the ε2 allele did not confer protection against the risk for dementia or AD. Gender and age at diagnosis were significant factors.
In our analysis of 123 patients with AD and 140 patients with dementia, there was no relation between APOE ε4 and AD or dementia in the Yoruba. These results using data from all the prevalence and incidence waves of our study are consistent with our earlier observation that ε4 is not a significant risk factor for AD in Nigerians.7 The results were similar if the prevalence and incident cases were analyzed separately. The strength of using incident cases is that case accrual is unlikely to have been affected by differential mortality between AD cases and healthy subjects and between genotype groups within AD. As shown in a previous article,13 we did not find an association between ε4 and mortality risk. However, having dementia significantly increased the risk for mortality.14
The lack of association contrasts with our previous findings of increased risk for AD with ε4/ε4 in African Americans.6 It is possible that the Yoruba ε4 carriers are dying earlier of other diseases, such as, cardiovascular disease. However, the ε4 allele frequency is not significantly different in the two cohorts (0.217 vs 0.218).6 Interestingly, the Yoruba have a lower incidence of both vascular disease and vascular risk factors including hypertension than did the African Americans. 15 Also, cholesterol and lipid levels are much lower in the Yoruba.
This lack of association together with the low incidence rate of AD makes the Yoruba an interesting population to study,7,8 especially in contrast with the African Americans. Both genetic and environmental factors may be responsible. There may be more variation within the African genome.16 We do not know how similar these two cohorts are genetically. The increased incidence of AD and the association with ε4 in the African Americans could be due to admixture. In addition, environmental risk factors that may play a role in AD (ie, high-fat diet and vascular disease) are not as common in the Yoruba. We are continuing to explore these possibilities in these two cohorts.
This research was supported by NIH (National Institute of Aging, RO1 AG09956, O.G., A.O., D.B., B.F., F.W.U., R.M.E., V.S-G., K.A.L., S.G., K.A.H., M.C.H., J.R.M.; P30 AG10133, F.W.U., R.M.E., K.A.L., S.G., H.C.H., J.R.M.).
We acknowledge the Ibadan community for their support and cooperation.